UK Guidelines on the Diagnosis and Treatment of Breast
Implant-Associated Anaplastic Large Cell Lymphoma on behalf of
the Medicines and Healthcare products Regulatory Agency
Plastic, Reconstructive and Aesthetic Surgery Expert Advisory
Group

J 2021

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

TURTON, P., D. EL-SHARKAWI, I. LYBURN, B. SHARMA, P. MAHALINGAM et. al.

Základní údaje

Originální název

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

Autoři

TURTON, P., D. EL-SHARKAWI, I. LYBURN, B. SHARMA, P. MAHALINGAM, Suzanne Dawn TURNER (826 Velká Británie a Severní Irsko, garant, domácí), F. MACNEILL, L. JOHNSON, S. HAMILTON, C. BURTON a N. MERCER

Vydání

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.615

Kód RIV

RIV/00216224:14740/21:00124572

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1111/bjh.17194

UT WoS

000591173100001

Klíčová slova anglicky

BIA‐ALCLreconstructive breast surgerylymphomabreast implantstreatment guidelines

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 5. 2022 15:17, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the aspirated peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK)-negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimise the need for systemic treatments, reduce morbidity and the risk of poor outcomes.

Citovat

TURTON, P., D. EL-SHARKAWI, I. LYBURN, B. SHARMA, P. MAHALINGAM, Suzanne Dawn TURNER, F. MACNEILL, L. JOHNSON, S. HAMILTON, C. BURTON a N. MERCER. UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group. BRITISH JOURNAL OF HAEMATOLOGY. 2021, roč. 192, č. 3, s. 444-458. ISSN 0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.17194.

@article{1852564,
   author = {Turton, P. and ElandSharkawi, D. and Lyburn, I. and Sharma, B. and Mahalingam, P. and Turner, Suzanne Dawn and MacNeill, F. and Johnson, L. and Hamilton, S. and Burton, C. and Mercer, N.},
   article_number = {3},
   doi = {http://dx.doi.org/10.1111/bjh.17194},
   keywords = {BIA‐ALCLreconstructive breast surgerylymphomabreast implantstreatment guidelines},
   language = {eng},
   issn = {0007-1048},
   journal = {BRITISH JOURNAL OF HAEMATOLOGY},
   title = {UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/bjh.17194},
   volume = {192},
   year = {2021}
}

TY  - JOUR
ID  - 1852564
AU  - Turton, P. - El-Sharkawi, D. - Lyburn, I. - Sharma, B. - Mahalingam, P. - Turner, Suzanne Dawn - MacNeill, F. - Johnson, L. - Hamilton, S. - Burton, C. - Mercer, N.
PY  - 2021
TI  - UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group
JF  - BRITISH JOURNAL OF HAEMATOLOGY
VL  - 192
IS  - 3
SP  - 444-458
EP  - 444-458
SN  - 00071048
KW  - BIA‐ALCLreconstructive breast surgerylymphomabreast implantstreatment guidelines
UR  - https://onlinelibrary.wiley.com/doi/10.1111/bjh.17194
N2  - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the aspirated peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK)-negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimise the need for systemic treatments, reduce morbidity and the risk of poor outcomes.
ER  -

TURTON, P., D. EL-SHARKAWI, I. LYBURN, B. SHARMA, P. MAHALINGAM, Suzanne Dawn TURNER, F. MACNEILL, L. JOHNSON, S. HAMILTON, C. BURTON a N. MERCER. UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group. \textit{BRITISH JOURNAL OF HAEMATOLOGY}. 2021, roč.~192, č.~3, s.~444-458. ISSN~0007-1048. Dostupné z: https://dx.doi.org/10.1111/bjh.17194.

Podrobný výpis o publikaci